Compound identified that improves heart function in rats

Credit: CC0 Public Domain

Heart attack survivors may think the worst is behind them. But many later develop heart failure, a progressive disease marked by shortness of breath and swelling in the legs. Symptoms can prevent patients from working, exercising—even picking up grandchildren.

Heart failure occurs after a when enough of the dies, causing the rest of the heart to overwork, which leads to more damage. To protect an overworked, failure-prone heart, cardiologists typically prescribe medications that encourage the heart to take it easy, said Daria Mochly-Rosen, Ph.D., professor of chemical and and the George D. Smith Professor in Translational Medicine.

Mochly-Rosen is hoping to tackle heart failure at the molecular level. She and her colleagues developed a compound that in preliminary tests appeared to improve in rats with heart failure caused by a heart attack.

The study was published Jan. 18 in Nature Communications. Julio Ferreira, Ph.D., a professor at the University of Sao Paulo, is the lead author.

One contributor to heart failure following a heart attack is the accumulation of broken or dysfunctional mitochondria, the small organelles in cells that produce energy. The researchers identified a pair of proteins that, when bonded, gum up the normal activity of mitochondria and contribute to heart failure. One of those proteins, protein kinase C beta 2, is found in higher levels in failing human and rodent hearts.

The researchers tapped their chemistry know-how to develop a compound called SAMβA (pronounced "samba"), which can prevent these proteins from bonding, thereby improving mitochondrial function and providing more energy for the heart.

In tests, post-heart-attack rats that developed and were treated with SAMβA had better cardiac function—measured by how well their left heart ventricles pumped blood with each —than rats that weren't treated with SAMβA.

"We greatly improved their hearts," Mochly-Rosen said. "If humans are going to be like rats, perhaps we can treat them with a drug that prevents this deterioration."

She added that they also gave healthy rats doses of SAMβA "and it had absolutely no effect," an indication that the compound is nontoxic.

Mochly-Rosen and Ferreira suspect that SAMβA will also be effective in humans. If so, it has the potential to be developed into a drug for human heart attack patients, they believe.

"I'm hopeful SAMβA will be accepted by the industry for because it appears very promising," Mochly-Rosen said.

More information: Julio C. B. Ferreira et al. A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats, Nature Communications (2019). DOI: 10.1038/s41467-018-08276-6

Journal information: Nature Communications
Citation: Compound identified that improves heart function in rats (2019, January 28) retrieved 27 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Heart failure takes heavy toll, even for those with stronger hearts


Feedback to editors